Sezai holds a MBA from the University of Basel and brings 20 years of pharmaceutical industry experience. He started his career in finance and moved to commercial roles. Sezai was a recognized business leader in hematology and oncology at Roche, Abbvie and AZ, at the regional and international level. He supervised the launch, marketing and commercialization of numerous leading franchises across multiple therapeutic areas. Among others he launched PERJETA, Kadcyla, TECENTRIQ, VECLYXTO and ENHERTU across different hematology and solid tumor indications. In his last role he helped to build up the alliance of AZ and Daiichi Sankyo in Europe. At owkin, Sezai is responsible for the strategic partnerships with pharma and biotech companies.